AI-driven clinical surveillance solutions provider CLEW has launched its Sepsis Virtual Unit (SVU) to enhance SEP-1 compliance and improve patient outcomes.
The system offers real-time AI-powered monitoring, enabling healthcare organisations to detect sepsis earlier, ensure timely interventions, and ensure compliance.
The Centres for Medicare & Medicaid Services (CMS) has increased enforcement of SEP-1 compliance, imposing fines on hospitals based on adherence to sepsis treatment protocols.
From 2024, CMS has linked SEP-1 performance to Value-Based Purchasing (VBP) incentives, where non-compliance will reduce reimbursements and increase penalties.
CLEW’s SVU device helps hospitals mitigate the changes by providing centralised, real-time monitoring, automated SEP-1 bundle tracking, and actionable insights.
The system allows providers to reduce their sepsis-related mortality, optimise workflows, and safeguard reimbursements.
The CLEW SVU easily integrates with any electronic medical record (EMR) system and ensures quick adoption without disrupting existing workflows.
CLEW’s Sepsis Virtual Unit empowers organisations to deliver higher-quality care, reduce sepsis-related penalties, and improve both clinical and financial outcomes.
CLEW product VP Noa Berger said: “Sepsis remains one of the leading causes of hospital mortality and costs, and regulatory requirements continue to push for better compliance and outcomes.
“Our Sepsis Virtual Unit provides organisations with the tools they need to detect sepsis earlier, improve protocol adherence, and ultimately save more lives.”
Last year, CLEW announced the Food & Drug Administration (FDA) 510(k) clearance for its second-generation, AI/machine-learning models for predicting patient deterioration.
The FDA 510(k) approval follows FDA approval as a class II medical device in 2021.
Leveraging unique machine-learning-driven prediction models and rule-based best practices, the CLEW platform enables health systems to early detect patients at risk of deterioration.
